Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV
- PMID: 32132669
- PMCID: PMC7091851
- DOI: 10.1038/s41423-020-0385-z
Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV
Conflict of interest statement
The authors declare no competing interests.
Figures
Comment on
-
Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.Emerg Microbes Infect. 2020 Feb 17;9(1):382-385. doi: 10.1080/22221751.2020.1729069. eCollection 2020. Emerg Microbes Infect. 2020. PMID: 32065055 Free PMC article.
References
-
- World Health Organization (WHO), Statement on the second meeting of the International Health Regulations (2005). Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-....
-
- Gorbalenya AE. Severe acute respiratory syndrome-related coronavirus – The species and its viruses, a statement of the Coronavirus Study Group. bioRxiv. 2020;382:727–733.
-
- Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV) Biosci. Trends. 2020;9:382–385. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- 31570758/National Natural Science Foundation of China (National Science Foundation of China)/International
- 91743115/National Natural Science Foundation of China (National Science Foundation of China)/International
- 31270797/National Natural Science Foundation of China (National Science Foundation of China)/International
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
